Particularly given the availability of drugs to target tumor-promoting signaling pathways negatively regulated by PTEN, an accurate understanding of how PTEN mutations arise, contribute to tumor presentation, and influence outcomes is of value. The gene discussed is PTEN; the disease is neoplasm.